Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses

Stock News

07/22

Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.

According to the lapsed document, Bonsun Pharmaceuticals is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1170452620"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170452620\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170452620?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170452620","market":"nz","top_or_hot":-1,"title":"Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses","media":"Stock News","content":"<p>Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.<br><br>According to the lapsed document, <b>Bonsun Pharmaceuticals</b> is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-07-22 09:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.<br><br>According to the lapsed document, <b>Bonsun Pharmaceuticals</b> is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).<br><br></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"歐康維視生物-B","start_time":0,"source_url":"","article_id":"1170452620","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170452620","pubTimestamp":1784683099,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","KCAI":"KraneShares China Alpha Index ETF","REDS":"RPM Republican Senate ETF","FRHC":"Euronext CAC Health Care","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","IPOS":"Renaissance International IPO ETF","BK4127":"投资银行业与经纪业","KCE":"SPDR KBW Capital Markets ETF"},"translate_title":"邦生制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"01477":1,"KCAI":1,"VXUS":1,"REDS":1,"KCE":1,"FRHC":1},"content_text":"Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.According to the lapsed document, Bonsun Pharmaceuticals is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}